Ⅲ期非小细胞肺癌新辅助放化疗达根治剂量后三联治疗的肿瘤学结局及影响手术考量的因素
该研究回顾性分析2000至2013年355例局部晚期非小细胞肺癌患者,比较接受手术的三联治疗、计划双联治疗与未计划双联治疗的生存与无复发生存。三联治疗中位生存59.9个月,优于后两者(20.1与17.3个月,P<.001);达到纵隔淋巴结清除时,ⅢB期与N3患者仍获益。种族、分期、体能状态、年龄及COPD诊断影响手术选择。
要点
- 三联治疗中位生存59.9个月,显著优于计划双联20.1个月与未计划双联17.3个月(P<.001)。
- 达到纵隔淋巴结清除时,ⅢB期(P<.001)与N3(P=.010)患者手术生存获益持续存在。
- 手术切除亦改善无复发生存(P=.001)。
核心结论
- 采用≥60 Gy根治剂量新辅助放化疗后行手术的三联治疗,可显著改善局部晚期非小细胞肺癌患者的生存与无复发生存。
- 种族、分期、体能状态、年龄及慢性阻塞性肺疾病诊断是影响初始选择三联治疗及实际实施手术的重要因素。
研究设计与样本
- 采用Kaplan-Meier法估计总生存与无复发生存,Cox比例风险回归前向选择法行多因素分析,Fisher精确检验用于列联表。
主要发现
- 三联治疗、未计划双联治疗与计划双联治疗的中位生存分别为59.9、20.1与17.3个月(P<.001)。
- 达到纵隔淋巴结清除时,ⅢB期(P<.001)与N3(P=.010)患者的手术生存获益持续存在。
- 手术切除改善无复发生存(P=.001)。
- 种族(P<.001)、分期(P<.001)、体能状态(P<.001)、年龄(P<.001)及慢性阻塞性肺疾病诊断(P=.009)影响初始选择三联治疗及实际实施手术的决策。
关键数值与推荐
- 新辅助放化疗根治剂量界定为≥60 Gy。
- 原文提及既往术前剂量45-50.4 Gy与纵隔淋巴结清除率低相关。
- 指南推荐cN2-N3期局部晚期非小细胞肺癌行根治性放化疗,手术保留给初诊时淋巴结受累轻微者。
临床怎么用
- 对初诊评估可手术的Ⅲ期患者,若采用≥60 Gy新辅助放化疗并达到纵隔淋巴结清除,可考虑手术以改善生存与无复发生存。
- 初诊决策需综合种族、分期、体能状态、年龄及COPD诊断等因素评估手术可行性。
局限性
- 为单中心回顾性分析,存在选择偏倚可能。
- 手术组与非手术组之间可能存在不可测量的基线差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Guidelines for locally advanced non-small cell lung cancer (LA-NSCLC) recommend definitive chemoradiation therapy (CRT) for cN2-N3 disease, reserving surgery for patients with minimal nodal involvement at presentation. The current literature suggests that surgery after CRT for stage III NSCLC can improve freedom-from-recurrence (FFR) but has not consistently demonstrated an improvement in overall survival, perhaps partly due to the low (45-50.4 Gy) preoperative doses delivered that result in low rates of mediastinal nodal clearance. We therefore analyzed factors associated with trimodality therapy receipt and determined outcomes in patients with LA-NSCLC who were treated with definitive doses (≥60 Gy) of neoadjuvant CRT prior to surgery. METHODS AND MATERIALS: We retrospectively analyzed 355 consecutive patients with LA-NSCLC who were treated with curative intent between January 2000 and December 2013. The Kaplan-Meier method was used to estimate the overall survival and FFR of patients who were initially planned to receive trimodality treatment but never underwent surgery (unplanned bimodality) compared with those who were never considered to be surgical candidates (planned bimodality) and those who underwent surgical resection after CRT (trimodality). Cox proportional hazards regression with forward selection was used for multivariate analyses, and the Fisher exact test was used to test contingency tables. RESULTS: Patients who received trimodality therapy had a longer median survival than those with unplanned or planned bimodality therapy at 59.9, 20.1, and 17.3 months, respectively (P < .001). The survival benefit with surgery persisted in patients with stage IIIB (P < .001) and N3 (P = .010) nodal disease when mediastinal nodal clearance was achieved. FFR was also improved with surgical resection (P = .001). Race (P < .001), stage (P < .001), performance status (P < .001), age (P < .001), and diagnosis of chronic obstructive pulmonary disease (P = .009) were significant indicators that influenced both the decision to initially choose trimodality therapy at consultation and to actually perform surgical resection. CONCLUSIONS: Trimodality treatment significantly improves survival and FFR in patients with LA-NSCLC when definitive doses of radiation with neoadjuvant chemotherapy are employed. We identified important demographic features that predict the use of surgical intervention in patients with stage III NSCLC.
引用
- Vyfhuis MAL, Bhooshan N, Burrows WM, et al. Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer. Adv Radiat Oncol. 2017. PMID: 29114590. doi:10.1016/j.adro.2017.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。